This initiative provides early stage translational support to identify and characterize potential therapeutic candidates and combination products for HLBS diseases and disorders. It aims to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates cleared for human testing, excluding clinical trials. The program supports product definition and lead series identification activities.
Eligible applicants include a wide range of organizations such as nonprofits, institutions of higher education, small businesses, government entities, tribal organizations, and others. Non-domestic (non-U.S.) entities are not eligible, but foreign components of U.S. organizations are allowed.
